PP01.118 First-line Nivolumab (N) + Ipilimumab (I) + Chemotherapy (C) in Metastatic NSCLC (mNSCLC): CheckMate 9LA 4-Year Clinical Update
Year: 2024
Type: conference-abstract
Source: Journal of Thoracic Oncology
Authors: Firas Badin, David P. Carbone, Tudor-Eliade Ciuleanu, Michael Schenker, Manuel Cobo-Dols, Stephanie Bordenave, Oscar Juan-Vidal, Juliana Menezes, Niels Reinmuth, Eduardo Richardet, Ying Cheng, Hideaki Mizutani, Luis G. Paz-Ares, Shun Lu, Thomas John, Xiaoqing Zhang, Nan Hu, David Balli, Vipul Baxi, Jaclyn Neely, Martin Reck
Institutions: Central Baptist Hospital, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Iuliu Hațieganu University of Medicine and Pharmacy, Institute of Oncology Prof. Dr. Ion Chiricuta, Romanian Society of Nephrology, Hospital Clínico Universitario Virgen de la Victoria, Instituto de Investigación Biomédica de Málaga, Institut du Thorax, Hospital Universitari i Politècnic La Fe, Asklepios Fachkliniken München-Gauting, Instituto Oncológico de Córdoba, Jilin Province Tumor Hospital, Saitama Cancer Center, Universidad Complutense de Madrid, Hospital Universitario 12 De Octubre, Shanghai Jiao Tong University, Shanghai Chest Hospital, Austin Hospital, Bristol-Myers Squibb (United States), German Center for Lung Research, LungenClinic Grosshansdorf
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W4400452804